Abhishek A. Mangaonkar
Mayo Clinic in Rochester
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Abhishek A. Mangaonkar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05005182 · Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring SideroblastsMayo Clinic · terminated · Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 11:09 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.Am J Hematol · 201964 citationsRCR 2.4
- Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia.Blood · 202046 citationsRCR 1.8
- Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia.Blood Cancer J · 202030 citationsRCR 1.6
- Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell disease.Br J Haematol · 202024 citationsRCR 1.4
- 24 citationsRCR 3.0
- 3 citationsRCR 0.1
- Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study.Blood Neoplasia · 20252 citationsRCR 0.5